AN ALTERNATIVE METHYLATION ROUTE - C&EN Global Enterprise

Apr 18, 2011 - Methylation of RNA typically involves transferring a methyl group from the ... S-adenosylmethionine, reported Squire J. Booker of Penns...
0 downloads 0 Views 1MB Size
SCIENCE & TECHNOLOGY

MAKING METHYL Unlike typical methyltransferases, RlmN and Cfr use only a methylene fragment from the common methyl donor S-adenosylmethionine (SAM) to build methyl groups on an adenine (image, orange) in the ribosome.

NH2

J. A M. C HEM. SOC.

O

N

H O O

N

NH2

N N

H

CH3-SAM

O

N

H O

RlmN

O

OH

N

NH2

N N

CH2H

OH

AN ALTERNATIVE METHYLATION ROUTE ACS MEETING NEWS: Details of bacterial enzymes’ unusual

methylation step may help fight antibiotic resistance

TWO BACTERIAL ENZYMES that install

methyl groups on ribosomal RNA do so by a surprising mechanism, according to two independent groups reporting at last month’s American Chemical Society

meeting in Anaheim, Calif. Because one of these methylations helps bacteria evade antibiotics, learning more about how these enzymes work may guide those hoping to sidestep antibiotic resistance.

WWW.CEN-ONLINE.ORG

42

AP RI L 1 8, 20 1 1

CH3-SAM Cfr

HH2C O

O

N N O

N N

CH2H

OH

Methylation of RNA typically involves transferring a methyl group from the common methyl donor S-adenosylmethionine to an RNA base. But the enzyme Cfr and its close cousin RlmN instead assemble a methyl group on their ribosomal adenosine substrate using only a methylene fragment from S-adenosylmethionine, reported Squire J. Booker of Pennsylvania State University and Danica Galonic´ Fujimori of the University of California, San Francisco. The enzymes are thus better described as methyl synthases, rather than the methyltransferases they were expected to be when Fujimori and coworkers first studied them last year (C&EN, March 29, 2010, page 9;

Aryl-homopiperazines Tosoh Organic Chemical, leading producer of piperazines, presents:

J. Am. Chem. Soc., DOI: 10.1021/ja910850y). Booker, graduate student Tyler L. Grove, and coworkers recently published their work in Science (DOI: 10.1126/ science.1200877); Fujimori and postdoc Feng Yan’s work recently appeared in Proceedings of the National Academy of Sciences USA (DOI: 10.1073/pnas.1017781108). In Anaheim, Booker and Fujimori described their work in separate sessions in the Division of Biological Chemistry. Both Booker and Fujimori suggested Cfr and RlmN may have seized upon this unusual pathway because both enzymes are charged with the demanding task of methylating nonnucleophilic centers. Most methyltransferases target nucleophilic centers, according to enzymologist Perry A. Frey of the University of Wisconsin, Madison. The difficulty inherent in methylating adenine’s nonnucleophilic C2 and C8 “requires a new chemical mechanism for methyl transfer by S-adenosylmethionine,” Frey explained.

1,4-diazacycloheptane or Homopiperazine (CAS 505-66-8)

HN

NH

And its aryl substituted derivatives by patented Tosoh Technology:

X

+

HN

NH

Patented Tosoh catalyst

ON THE BASIS of isotopic labeling

data, the two groups propose different mechanisms for how the enzymes work. A notable difference in their proposals is whether a cysteine in the active site might serve to transfer the methylene fragment from S-adenosylmethionine to the adenine substrate. Adding weight to Booker’s proposal that it might, Amie K. Boal, a postdoc in Amy C. Rosenzweig’s group at Northwestern University, presented an unpublished 2.05-Å crystal structure of RlmN at the meeting. The structure, solved in collaboration with Booker’s group, contains a methylated cysteine near S-adenosylmethionine’s binding site, she reported. The adenine that both enzymes methylate is at the catalytic heart of the bacterial ribosome, where proteins are built. Although the methyl group that RlmN installs serves to optimize normal ribosomal function, the one that Cfr appends makes bacteria resistant to certain antibiotics. Among the antibiotics rendered inactive by Cfr’s handiwork are the oxazolidinones, a class of synthetic drugs currently used to treat multi-drugresistant bacteria. Understanding the mechanism by which Cfr confers resistance to these drugs could teach drug designers how to outwit it, Fujimori suggested. What’s more, Booker said, the mechanism of these enzymes might inform chemists’ continuing efforts to functionalize unactivated carbons.—AMANDA YARNELL WWW.CEN-ONLINE.ORG

43

AP RI L 1 8, 20 1 1

R N

NH